Evofem Biosciences, Inc. (EVFM) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Evofem Biosciences, Inc.

Why is Evofem Biosciences, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 79.14% and Operating profit at 14.55% over the last 5 years
The company has a negative book value of Rs 70.17 crore

The company has declared negative results in Mar'2026 after 2 consecutive positive quarters

INTEREST(9M) At USD 0.69 MM has Grown at inf%
OPERATING PROFIT(Q) Lowest at USD -4.46 MM
PRE-TAX PROFIT(Q) Lowest at USD -5.3 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -8.60%, its profits have risen by 59.6%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -8.60% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

83.37%

EBIT Growth (5y)

15.03%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.02

EV to EBIT

38.26

EV to EBITDA

26.66

EV to Capital Employed

-3.55

EV to Sales

2.73

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -0.25 MM

NET SALES(HY)

At USD 10.46 MM has Grown at 31.59%

NET PROFIT(HY)

Higher at USD -2.65 MM

RAW MATERIAL COST(Y)

Fallen by -53.18% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 23.68 times

-18What is not working for the Company

INTEREST(9M)

At USD 0.69 MM has Grown at inf%

OPERATING PROFIT(Q)

Lowest at USD -4.46 MM

PRE-TAX PROFIT(Q)

Lowest at USD -5.3 MM

NET PROFIT(Q)

Lowest at USD -5.3 MM

EPS(Q)

Lowest at USD -0.04

Here's what is working for Evofem Biosciences, Inc.

Operating Cash Flow

Highest at USD -0.25 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

At USD 10.46 MM has Grown at 31.59%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Debtors Turnover Ratio

Highest at 23.68 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -53.18% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Evofem Biosciences, Inc.

Interest

At USD 0.69 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -5.3 MM has Fallen at -1,696.44%

over average net sales of the previous four periods of USD -0.3 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -5.3 MM has Fallen at -1,693.07%

over average net sales of the previous four periods of USD -0.3 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -4.46 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -5.3 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -5.3 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.04

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)